Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-125 with Radiation in Newly Diagnosed Glioblastoma
NCT07185880Phase 2Recruiting
- Sponsor
- Myosin Therapeutics
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MT-125 in glioblastoma (GBM), sponsored by Myosin Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
MT-125
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07185880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185880.